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tation, we attempted to define standards for 
scientific, research, and clinical practicality 
illustrating ideal or aspirational PRO measu-
re development and implementation [3-12].
PROs fROm ReseaRch 
tO PRactice tO POlicy: 
a fRamewORk
As a result of this review, we propose four sta-
ges that frame the translation of PROs from 
research to practice to policy (Figure 1). Sta-
ge one, issue identification, is to ensure that 
PROs are targeting meaningful clinical areas 
and assessing domains of healthcare delive-
ry that other quality metrics cannot, such as 
health-related quality of life and experience 
with care. As stakeholders continue to que-
stion whether PRO data is meaningful to both 
the patient and the provider, research and te-
sting emerged as a key second step to make 
certain that a PRO measure is appropriate 
and usable to advance scientific knowledge. 
In the third phase, PRO measures in clinical 
practice will be able to predicate behavioral 
changes that drive quality improvement. And, 
if a PRO measure can successfully be imple-
mented in clinical practice, then it can enter 
the final phase for implementation into qua-
lity and performance measurement. In this 
stage, measures are utilized to assess value 
from the patient’s perspective in a way that is 
harmonized with PRO use in other settings.
In designing this framework, one of the ove-
rarching aims was to identify and put forth 
opportunities for patient engagement in the 
research, care, and quality processes. The 
growing emphasis on patient centeredness 
suggests that the use of well-developed PRO 
measures can safeguard patients’ needs and 
perspectives by assessing how treatment af-
fects them. In research, FDA’s Patient-Fo-
cused Drug Development (PFDD) provides 
patients with an opportunity to share input 
into clinical trial design and investment; the 
intROductiOn
Despite a lack of consensus on what consti-
tutes an ideal healthcare system, stakeholders 
have unanimously called for patient-cente-
redness as a national priority. In the midst 
of health reform, various health care entities 
(e.g. providers, hospitals, payers) have sou-
ght a deeper understanding of patient-repor-
ted outcomes (PROs), which reflect a pa-
tient’s direct input in assessments of quality 
of life and value for a particular treatment. 
In recent years, there have been numerous 
efforts to integrate well-validated PROs into 
electronic health records, indicating growth 
in their importance [1].
Regardless of this interest and growth, seve-
ral key gaps still remain in the development 
and routine use of PROs. For example, while 
PRO measures exist and are used in clinical 
trials, few are at the point of care in daily 
clinical practice, and even fewer are transla-
ted into quality and performance measures 
(tying payment to value in public and private 
programs in the U.S., Europe, and Canada). 
Furthermore, the PRO measures that do exist 
lack validation. Significant work needs to be 
done in order to incorporate greater input to 
measure self-reported health condition out-
comes of greatest interest to the patient and 
account for gaps. One solution is a rigorous, 
step-wise, and nimble PRO development and 
translation approach that accommodates new 
information and best practices as they emer-
ge [2].
In an effort to better understand the barriers 
around translation and conceptualize what 
exactly this nimble and step-wise process 
could resemble, we developed a translation 
framework to bridge the gap between inte-
gration of PROs into clinical trials and adop-
tion into value-based reimbursement. Based 
on a survey of publicly-available literature 
from organizations that have historically had 
a role in PRO development and implemen-
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use of PROs can help prioritize and capture 
endpoints that matter most to patients as well 
as enhance the benefit-risk assessment in re-
gulatory decision making for biopharmaceu-
tical products [15]. PROs can also heighten 
patient engagement in care processes, as they 
may provide guidance in determining patient 
health goals. Finally, robust PROs can sup-
port efforts to define value in the healthca-
re system more broadly and capture what is 
truly important to the patient.
Avalere is neither the first, nor the last, sta-
keholder to dedicate time and thought to the 
issue of PRO translation from clinical trial 
to value-based reimbursement and the asso-
ciated challenges. For example, the National 
Quality Forum (NQF) and the Patient-Cen-
tered Outcomes Research institute (PCORI) 
are focusing their efforts on the technical 
concerns related to the translation of PRO 
measures for use as performance measures 
[16-18]. Additionally, England’s National 
Health Service has examined PRO measu-
re data collection methods and associated 
opportunities to optimize patient respon-
se rates. In the context of this developing 
field, the stages identified in our framework 
put forward a process that begins to address 
some of the broader technical and methodo-
logical concerns with PRO translation. Incre-
ased attention on PRO translation is expected 
in the future; European countries have alre-
ady made substantial progress towards the 
shift, and Health and Human Services (HHS) 
recently announced a goal of tying payment 
to value through alternative payment models 
and participation in reporting programs. The 
framework provides guidance on translating 
PROs from use to actual measurement that 
can be linked to payment.
cOnclusiOns
In the face of increased attention and activity 
around PRO translation, how can we ensu-
re that patients are genuinely consulted and 
engaged throughout the PRO translation pro-
cess? One possible place is determining whe-
ther patients are fully engaged throughout 
each of the four steps in our framework. For 
example, under the research and testing step, 
there is an opportunity for patients to play 
a role, thereby helping to determine if the 
PRO measure is fit for purpose. Still, thou-
gh the framework provides a potential path 
forward in the PRO translation environment, 
considerable work still remains before such a 
framework can be implemented and adopted 
widely. Before we can move forward with 
entering measures through the framework, 
we must ensure that they are truly designed 
with the patient perspective in mind, and to 
that end, measure what matters most to pa-
tients: “Can I dance with my granddaughter 
at her wedding?” or “Will I be able to walk 
up the stairs?” Increasingly we are seeing 
interest in developing PRO measures with 
somewhat less quantifiable patient-reported 
outcomes (e.g., compassion, hope). With this 
careful attention to measure development 
comes a realization that, in some instances, 
the measures that matter to patients may not 
Figure 1. Common Factors and Best Practices Across Four Stages of PRO Translation
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tient-centered efforts. While such efforts – our 
framework, included – are developed with the 
intent of placing patients at the center, there 
exists an opportunity to learn from best prac-
tices on how to execute on that vision and po-
sition ensure patients as partners throughout 
the development of patient-centered activities.
align with those that are of high priority for 
providers.
We must reconcile this tension as we continue 
to shift towards a patient-centered healthcare 
system. Stakeholders looking at the big pic-
ture must continue to be thoughtful and deli-
berate in including patients in developing pa-
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